Drug Safety15 August 2026

How paediatric safety information gets onto the label

The label is where paediatric evidence becomes usable at the bedside. US and EU rules now require results to reach it, even when the studies fail.

By NextGenHealth Editorial Team2 min read

Assorted colourful medication pills — Photo: pina messina / Unsplash

In brief

How paediatric study results reach drug labels under PREA, BPCA and the EU Paediatric Regulation, including negative results and key SmPC sections.

A paediatric study only helps children if its results reach the people prescribing. For years, many did not. Studies completed for exclusivity rewards could end with no change to the label, and negative results could go unpublished.

The US approach

Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, the results of paediatric studies must be reflected in labelling, whether they show the drug works in children, does not work, or raises safety concerns. The FDA maintains a public database of paediatric labelling changes, and summaries of its reviews are published.

That matters because a label stating that efficacy was not shown in children is useful information. It tells clinicians not to assume that adult results will carry over.

The EU approach

In the EU, paediatric information appears in specific sections of the summary of product characteristics. Section 4.2 covers posology, including paediatric doses or a statement that safety and efficacy have not been established. Section 4.8 covers adverse reactions, section 5.1 pharmacodynamic properties including paediatric trial results, and section 5.2 pharmacokinetics.

The Paediatric Regulation also required companies to submit paediatric studies they had already completed on authorised products, so that existing data could be assessed and added to labels. Results of paediatric trials must be posted in the EU’s clinical trial register.

Safety-specific updates

Labels also change in response to post-marketing safety signals, such as contraindications for particular age groups. Those changes are often the most consequential paediatric updates, and the slowest to reach practice.

The remaining gap

The rules apply going forward and to products whose sponsors seek rewards. Many older medicines used routinely in children still carry no paediatric information at all, which is why prescribing references written by clinicians remain essential.

Labelling
PREA
BPCA
SmPC
Transparency

More in Drug Safety. Pharmacovigilance, label changes and safety signals in children’s medicines.

Safety

How drug safety monitoring works when paediatric trials are small

Rare adverse events rarely show up in trials of a few hundred children. Post-marketing surveillance has to do the heavy lifting.
Safety

The codeine lesson: how one safety signal changed paediatric prescribing

A painkiller given to children for decades turned out to be dangerous for a genetically identifiable minority. The response remains a model for pharmacogenomic safety.
Safety

Why long-term follow-up matters more when the patient is a child

A medicine given to a child can affect growth, development and fertility years after the last dose. Trials end long before those effects would show.
Safety

Tenfold errors and other dosing mistakes in paediatric care

Weight-based dosing, liquid formulations and adult-sized products combine to make children unusually vulnerable to medication errors.
Safety

Antipsychotics in young people and the metabolic risk

Second-generation antipsychotics are increasingly prescribed to children and adolescents. Their effects on weight and metabolism appear to be greater than in adults.
All Drug Safety 6 articles

Policy

Why children still wait years for medicines adults already have

Two decades of incentives and mandates on both sides of the Atlantic have transformed paediatric drug development. They have not closed the gap.
Medicines

The formulation problem: making adult drugs work for small bodies

A tablet that suits a 70kg adult is often useless for a toddler. Getting the dose, the taste and the ingredients right is a development programme in its own right.
Evidence

Extrapolation is changing how paediatric trials are designed

Regulators increasingly accept that adult efficacy data can carry over to children when the disease and the drug’s effect are similar enough. The argument is about how much.
Treatments

Gene therapy’s pipeline is overwhelmingly paediatric

Many of the conditions that one-time genetic treatments target first appear in infancy. That puts children at the centre of the field’s scientific, commercial and ethical debates.
Conditions

Rare diseases set the agenda for paediatric drug development

Many rare conditions begin in childhood, so orphan drug incentives and paediatric rules increasingly pull in the same direction.
Policy

What the EU pharmaceutical reform means for children’s medicines

Brussels’ overhaul of its medicines legislation folds the Paediatric Regulation into a single framework. The details will decide whether plans for children start earlier.